Patent 11186596 was granted and assigned to ADT Pharmaceuticals, LLC on November, 2021 by the United States Patent and Trademark Office.
Disclosed are compounds for medical uses, for example, compounds of formula (Ia), wherein A1, A2, A3, A4, A5, A6, A7, R6, R7 and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.